Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track

Beam Therapeutics Inc.

2026-Q1 EPS reported -$0.91 revenue$31,738,000

BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.
Risto-cel (BEAM-101) Phase 1/2 data published in NEJM; BLA submission expected as early as year-end 2026 for sickle cell disease.
Cash, cash equivalents and marketable securities were $1.2 billion as of March 31, 2026; cash runway into mid-2029.
Net loss of $94.3 million ($0.91 per share) for Q1 2026, compared to net loss of $108.3 million ($1.23 per share) in Q1 2025.
IND filing for BEAM-304 in PKU and initial data for BEAM-301 in GSDIa expected in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210299

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.